Table 2.
Unadjusted (n = 2,933) | Demographic Variable† Adjusted (n = 2,933) | Comorbidity‡ Adjusted (n = 2,873) | |
---|---|---|---|
Composite Activity Score | |||
| |||
2 (n = 310, 10.6%) | Reference | Reference | Reference |
3 (n = 461, 15.7%) | 0.74 (0.54–1.02) | 0.79 (0.58–1.09) | 0.75 (0.53–1.04) |
4 (n = 600, 20.5%) | 0.52 (0.38–0.71) | 0.56 (0.41–0.76) | 0.56 (0.40–0.78) |
5 (n = 688, 23.5%) | 0.52 (0.38–0.70) | 0.52 (0.38–0.70) | 0.53 (0.39–0.74) |
6 (n = 582, 19.8%) | 0.58 (0.42–0.78) | 0.60 (0.44–0.82) | 0.60 (0.43–0.84) |
7 (n = 292, 10.0%) | 0.48 (0.33–0.71) | 0.46 (0.31–0.69) | 0.50 (0.33–0.76) |
| |||
Test for trend | p < 0.001 | p < 0.001 | p = 0.001 |
Values are odds ratio (95% confidence interval).
Increase from baseline >25% and a follow-up NT-proBNP of >190 pg/ml. All models additionally adjusted for baseline NT-proBNP.
Demographic variables: age, sex, race, and education.
Comorbidities: body mass index, diabetes, hypertension, coronary heart disease, claudication, emphysema, stroke, major electrocardiographic abnormality, and self-reported health.
NT-proBNP = N-terminal pro–B-type natriuretic peptide.